COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Lantus Effect on Myocardial Glucose Metabolism in T2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00335465
Recruitment Status : Completed
First Posted : June 9, 2006
Last Update Posted : December 7, 2009
Information provided by:

Brief Summary:

The primary objective of the present study is to assess changes of myocardial glucose uptake (MGU) during clamp studies using positron emission tomography (PET) scanning in patients with type 2 diabetes and idiopathic left ventricular dysfunction (LVD).

The secondary objectives of the study are: assessment of changes of myocardial microcirculation at rest and during adenosine stimulation using PET; assessment of changes in myocardial structure and function evaluated by magnetic resonance imaging (MRI); assessment of glycaemic control by measurement of HbA1c, fasting blood glucose and insulin levels; assessment of safety (adverse event profile, laboratory data).

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Drug: Insulin glargine Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study for the Evaluation of the Effects of Insulin Treatment on Myocardial Function, Perfusion, and Glucose Metabolism in Patients With Primary Left Ventricular Dysfunction and Type 2 Diabetes.
Study Start Date : September 2005
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: Insulin glargine
    once a daily, sc injection, 100IU/ml

Primary Outcome Measures :
  1. effect of insulin treatment on myocardial function, perfusion and glucose metabolism. [ Time Frame: assessed before and after treatment ]
  2. adverse events [ Time Frame: throughout the study ]

Secondary Outcome Measures :
  1. changes of myocardial structure and left ventricular systolic and diastolic function [ Time Frame: at baseline and at the end of the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • LV systolic dysfunction (2D-Echo LVEF < 50%) with or without LV dilation (2D-Echo LV EDD > 56 mm) or left ventricular end-diastolic diameter (LVEDD) >55mm with or without LV dysfunction
  • angiographically normal coronary arteries (< 50% vessel narrowing);
  • newly diagnosed type 2 diabetes;
  • previously diagnosed: OAD treated type 2 diabetic patients able to take part in the study after a one-month wash-out period and insulin treated type 2 diabetic patients able to take part in the study after one week wash-out period.

Exclusion Criteria:

  • evidence of congenital or valvular cardiac diseases, hypertrophic cardiomyopathy, overt heart failure (NYHA class III-IV);
  • moderate to severe hypertension (diastolic aortic pressure > 100 mmHg);
  • hypotension (systolic aortic pressure < 100 mmHg);
  • nephropathy (serum creatinine > 3 mg/dL);
  • other systemic and/or infective diseases;
  • severe dyslipidemia;
  • peripheral vasculopathy;
  • necessity of vasoactive medical treatment in the last 48 hours;
  • atrial fibrillation;
  • Refusal or impossibility to give written informed consent;
  • patients diagnosed with type 1 insulin dependent diabetes;
  • clinically relevant cardiovascular, hepatic, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult;
  • patients with medical history positive for cerebrovascular accidents, including Transient Ischaemic Attack (TIA);
  • women who are lactating, pregnant, or planning to become pregnant during the study;
  • history of hypersensitivity to the investigational products or to drugs with similar chemical structures;
  • likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol;
  • treatment with any investigational product in the last 30 days or 5 half-lives (whichever is longer) before study entry;
  • current use of investigational agents or participation in any other investigational studies during study period;
  • history of drug or alcohol abuse;
  • impaired hepatic function, as shown by Alamine AminoTransferase (ALT) > 2,5 times the upper limit of the normal laboratory range;
  • mental condition making the subject unable to understand the nature, scope, and possible consequences of the study;
  • patients unable to understand dosing directions;
  • subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study procedures;
  • receipt of an experimental drug or use of an experimental device within the 30 days prior to study entry;
  • previous enrollment in the present study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00335465

Layout table for location information
Sanofi-Aventis Administrative Office
Milan, Italy
Sponsors and Collaborators
Layout table for investigator information
Study Director: Georges Paizis, MD Sanofi
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Medical Affairs Study Director, sanofi-aventis Identifier: NCT00335465    
Other Study ID Numbers: HOE901_4053
EUDRACT # : 2004-002729-34
First Posted: June 9, 2006    Key Record Dates
Last Update Posted: December 7, 2009
Last Verified: December 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin Glargine
Hypoglycemic Agents
Physiological Effects of Drugs